| Filed On | Filing |
|---|---|
| 13 Nov 2026 | SCHEDULE 13G/A |
| 10 Nov 2026 | SCHEDULE 13G |
| 04 Nov 2026 | 10-Q |
| 03 Nov 2026 |
8-K: Completion of Acquisition or Disposition of Assets; Results of Operations and Financial Condition +1 more
Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027 |
| 30 Oct 2026 | SCHEDULE 13G/A |
| 20 Oct 2026 | SCHEDULE 13G |
| 19 Oct 2026 |
Form 4: Horn Howard, Chief Financial Officer
Sold 7,066 shares ($108K) |
| 19 Oct 2026 |
8-K: Other Events
On October 19, 2026, Ultragenyx Pharmaceutical Inc. (the “Company”) and Baylor Research Institute (“BRI”) entered into a settlement agreement with Navinta LLC (“Navinta”) resolving patent litigation related to patents covering the Compan... |
| 14 Oct 2026 |
8-K: Entry into a Material Definitive Agreement
On October 8, 2026, Ultragenyx Pharmaceutical Inc. (the “Company”) entered into an asset purchase agreement (the “PRV Asset Purchase Agreement”), pursuant to which the Company agreed to sell a Rare Pediatric Disease Priority Review Vouch... |
| 07 Oct 2026 |
8-K: Entry into a Material Definitive Agreement
On October 6, 2026, Ultragenyx Pharmaceutical Inc. (the “Company”) entered into an asset purchase agreement (the “PRV Asset Purchase Agreement”), pursuant to which the Company agreed to sell a Rare Pediatric Disease Priority Review Vouch... |
| 17 Sep 2026 |
8-K: Other Events
On September 17, 2026, Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) announced that the U.S. Food and Drug Administration (the “FDA”) granted standard full approval of FAYUVI™ (rebisufligene etisparvovec-hopf), also know... |
| 15 Sep 2026 |
Form 4: Huizenga Theodore Alan, SVP, Chief Accounting Officer
Sold 1,283 shares ($17.4K) |
| 15 Sep 2026 | 144 |
| 08 Sep 2026 |
Form 4: Huizenga Theodore Alan, SVP, Chief Accounting Officer
Sold 161 shares ($2.25K) |
| 02 Sep 2026 |
8-K: Other Events
On September 2, 2026, Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) announced results from the Phase 3 Aspire study for apazunersen (GTX-102) in Angelman syndrome. The study did not achieve the primary endpoint of change... |
| 19 Aug 2026 |
8-K: Other Events
On August 19, 2026, Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) announced the U.S. Food and Drug Administration (the “FDA”) granted accelerated approval for GENGLYCOS™ (pariglasgene brecaparvovec-opnr), also known as D... |
| 14 Aug 2026 | SCHEDULE 13G |
| 13 Aug 2026 | SCHEDULE 13G |
| 11 Aug 2026 |
8-K: Other Events
On August 7, 2026, Ultragenyx Pharmaceutical Inc. (the “Company”) and Baylor Research Institute (“BRI”) entered into a settlement agreement with Esjay Pharma Private Limited and Esjay Pharma LLC (collectively, “Esjay”) resolving patent l... |
| 07 Aug 2026 | SCHEDULE 13G |
Loading...